Article info
Colorectal
Original research
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
- Correspondence to Dr Charles Miller, Gastroenterology, University College Hospital London, London, UK; charles.miller{at}nhs.net
Citation
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
Publication history
- Received May 10, 2021
- Accepted October 26, 2021
- First published January 7, 2022.
Online issue publication
August 05, 2022
Article Versions
- Previous version (7 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.